Literature DB >> 16985643

Bisphosphonates in metastatic prostate cancer.

Masood A Khan, Alan W Partin.   

Abstract

Entities:  

Year:  2003        PMID： 16985643      PMCID： PMC1473011     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  12 in total

Review 1.  Optimal hormonal therapy for advanced prostatic carcinoma.

Authors:  S Goktas; E D Crawford
Journal:  Semin Oncol       Date:  1999-04       Impact factor: 4.929

2.  Morphometric evidence for bone resorption and replacement in prostate cancer.

Authors:  N W Clarke; J McClure; N J George
Journal:  Br J Urol       Date:  1991-07

3.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

Authors:  G N Hortobagyi; R L Theriault; L Porter; D Blayney; A Lipton; C Sinoff; H Wheeler; J F Simeone; J Seaman; R D Knight
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

Review 4.  Bone metastases: improving the therapeutic index.

Authors:  H I Scher; L W Chung
Journal:  Semin Oncol       Date:  1994-10       Impact factor: 4.929

Review 5.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.

Authors:  B I Carlin; G L Andriole
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

6.  Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

Authors:  H R Maxon; L E Schroder; V S Hertzberg; S R Thomas; E E Englaro; R Samaratunga; H Smith; J S Moulton; C C Williams; G J Ehrhardt
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

Review 7.  Bisphosphonates in multiple myeloma.

Authors:  B Djulbegovic; K Wheatley; J Ross; O Clark; G Bos; H Goldschmidt; F Cremer; M Alsina; A Glasmacher
Journal:  Cochrane Database Syst Rev       Date:  2002

8.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.

Authors:  T Diamond; J Campbell; C Bryant; W Lynch
Journal:  Cancer       Date:  1998-10-15       Impact factor: 6.860

9.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

10.  The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

Authors:  Shiuw H Han; John M H de Klerk; Suzy Tan; Alfred D van het Schip; Bert H Derksen; Aalt van Dijk; Cas L J J Kruitwagen; Geert H Blijham; Peter P van Rijk; Bernard A Zonnenberg
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057
View more
  3 in total

1.  The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy.

Authors:  Ayhan Karaköse; Mehmet B Yüksel; Özgü Aydoğdu; Bilal Gümüş; Yusuf Z Ateşçi; Zafer Akan
Journal:  Curr Urol       Date:  2014-08-20

2.  Bone metastases in biliary cancers: A multicenter retrospective survey.

Authors:  D Santini; G Brandi; G Aprile; M Russano; S Cereda; F Leone; S Lonardi; L Fornaro; M Scartozzi; N Silvestris; S Barni; F Pantano; B Vincenzi; A Palloni; G Frega; M Casagrande; L Ferrari; V Dadduzio; R Intini; R Filippi; E Vasile; C Vivaldi; L Faloppi; O Brunetti; M Reni; M Aglietta; G Tonini
Journal:  J Bone Oncol       Date:  2018-04-07       Impact factor: 4.072

Review 3.  Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.

Authors:  Zintle Mbese; Blessing A Aderibigbe
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.